NEW HAVEN, Conn., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces it has entered into an agreement with a Japanese distributor for the sales and distribution of its products into the Japanese market. The distributor has already secured its first purchase order from a leading Japanese clinical laboratory, for Precipio’s proprietary IV-Cell cytogenetics media.

康涅狄格州纽黑文，2024年1月17日（环球通讯社）--专业癌症诊断公司Precipio，Inc.（纳斯达克：PRPO）宣布，它已经与一家日本分销商签订了一项协议，将其产品销售和分销到日本市场。分销商已经从日本领先的临床实验室获得了Precipio专有的IV细胞细胞遗传学培养基的第一份采购订单。

The first shipment is expected to be delivered at the end of Q1-2024. The Japanese diagnostic market is renowned for its high level of quality and for its intense scrutiny of products. Precipio was approached by a Japanese laboratory with an inquiry about its IV-Cell media, and entered into a testing period to evaluate the product.

预计第一批货物将于2024年第一季度末交付。日本诊断市场以其高质量和对产品的严格审查而闻名。一家日本实验室向Precipio咨询其IV细胞培养基，并进入测试期以评估产品。

The laboratory conducted extensive testing of Precipio’s IV-Cell cytogenetics media, including a comprehensive side-by-side analysis comparing it to the current media used in their lab. The study, results of which were shared with Precipio, demonstrated the superior performance of IV-Cell, and ultimately resulted in their decision to adopt the media in their laboratory.

该实验室对Precipio的IV细胞细胞遗传学培养基进行了广泛的测试，包括将其与实验室中使用的当前培养基进行全面的并行分析。该研究的结果与Precipio共享，证明了IV细胞的优越性能，并最终导致他们决定在实验室中采用该培养基。

The laboratory then appointed a distributor to handle negotiations with Precipio, resulting in a distribution agreement for its products within the Japanese market. The parties have entered into a multiple year commitment, with the intent of forming a long-term relationship to leverage the distributor’s network within Japan to distribute Precipio’s current, and future products, and bring diagnostic advancements to a broad range of customers in the Japanese market.

然后，实验室指定了一名分销商与Precipio进行谈判，从而达成了其产品在日本市场的分销协议。双方签订了多年承诺，旨在建立长期关系，利用日本境内的经销商网络分销Precipio当前和未来的产品，并为日本市场的广泛客户带来诊断进步。

“There is no greater demonstration of the quality and clinical utility of our product, than its acceptance by a premier lab in Japan. I’m extremely proud of our R&D team that has successfully create.

“我们的产品质量和临床实用性的最好证明，莫过于它被日本一流的实验室所接受。我为我们成功创建的研发团队感到无比骄傲。